Literature DB >> 12586176

Renin-angiotensin system in proliferative diabetic retinopathy and its gene expression in cultured human müller cells.

Teruyo Kida1, Tsunehiko Ikeda, Masato Nishimura, Tetsuya Sugiyama, Yutaka Imamura, Chie Sotozono, Kohji Nishida, Shigeru Kinoshita, Manabu Yoshimura, Kimitoshi Nakamura, Naoki Inokuchi.   

Abstract

PURPOSE: To determine if the renin-angiotensin system (RAS) is involved in diabetic retinopathy, we measured the levels of angiotensin-converting enzyme (ACE) and angiotensin II in the vitreous of patients with proliferative diabetic retinopathy (PDR). We also investigated whether the genes of the RAS factors were expressed by cultured human Müller cells.
METHODS: Vitreous samples were collected during vitreous surgery from patients with PDR, and from patients with idiopathic macular hole, who served as controls. The concentration of ACE was analyzed, and the level of angiotensin II was quantitatively determined by double antibody radioimmunoassay. In addition, the cDNA, prepared from the mRNA extracted from cultured human Müller cells, was used as a template for reverse transcriptase-polymerase chain reaction with primers selected for renin, angiotensinogen, ACE, and angiotensin receptor type I.
RESULTS: The mean concentration of ACE was 0.82 +/- 0.73 IU/L at 37 degrees C in the PDR group, which was significantly higher than the 0.05 +/- 0.07 IU/L at 37 degrees C in the controls. The mean concentration of angiotensin II was 8.77 +/- 4.57 pg/mL in the PDR group, which was significantly higher than the 5.1 +/- 1.7 pg/mL in the controls. mRNA for renin, angiotensinogen, ACE, and angiotensin receptor type I was detected in cultured human Müller cells.
CONCLUSIONS: The RAS is locally activated in eyes with PDR, and Müller cells may play a role in this local activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586176     DOI: 10.1016/s0021-5155(02)00624-x

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  8 in total

Review 1.  Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-( 1-12) Axis in the Pathogenesis of Diabetic Retinopathy.

Authors:  Mohammad Shamsul Ola; Abdullah S Alhomida; Carlos M Ferrario; Sarfaraz Ahmad
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

2.  Angiotensin receptor expression revealed by reporter mice and beneficial effects of AT2R agonist in retinal cells.

Authors:  Amrisha Verma; Ping Zhu; Annette de Kloet; Eric Krause; Colin Sumners; Qiuhong Li
Journal:  Exp Eye Res       Date:  2019-08-23       Impact factor: 3.467

Review 3.  Models of retinal diseases and their applicability in drug discovery.

Authors:  Goldis Malek; Julia Busik; Maria B Grant; Mayur Choudhary
Journal:  Expert Opin Drug Discov       Date:  2018-01-30       Impact factor: 6.098

4.  Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction.

Authors:  Toshihide Kurihara; Yoko Ozawa; Susumu Ishida; Hideyuki Okano; Kazuo Tsubota
Journal:  Int J Inflam       Date:  2012-03-22

5.  Microarray for genes associated with signal transduction in diabetic OLETF keratocytes.

Authors:  Ji-Eun Lee; Jong Soo Lee; Sang Ho Hwang
Journal:  Korean J Ophthalmol       Date:  2007-06

Review 6.  Therapeutic targets of renin-angiotensin system in ocular disorders.

Authors:  Rajesh Choudhary; Mandeep Singh Kapoor; Amrita Singh; Surendra H Bodakhe
Journal:  J Curr Ophthalmol       Date:  2016-10-20

7.  Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril.

Authors:  Preenie deS Senanayake; Vera L Bonilha; John W Peterson; Yoshiro Yamada; Sadashiva S Karnik; Firouz Daneshgari; K Bridget Brosnihan; Joe G Hollyfield
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Jul-Sep       Impact factor: 1.636

8.  Angiotensin-(1-7) Attenuates Protein O-GlcNAcylation in the Retina by EPAC/Rap1-Dependent Inhibition of O-GlcNAc Transferase.

Authors:  Sadie K Dierschke; Allyson L Toro; Alistair J Barber; Amy C Arnold; Michael D Dennis
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.